BioInvent International AB (publ) (STO:BINV)
2.090
-0.080 (-3.69%)
Nov 20, 2026, 5:29 PM CET
STO:BINV Revenue
BioInvent International AB had revenue of 10.79M SEK in the quarter ending September 30, 2026, with 224.99% growth. This brings the company's total for the last twelve months to 39.98M, down -83.67% year-over-year. In the year 2025, BioInvent International AB had annual revenue of 226.50M with 406.86% growth. That makes BioInvent International AB the 40,778th largest company in the world by revenue and 590th in Sweden.
Revenue (ttm)
39.98M
Revenue Growth
-83.67%
P/S Ratio
3.44
Revenue / Employee
373.66K
Employees
107
Market Cap
137.53M
Revenue by Geography
- USA 210.95M 93.1%
- Sweden 13.72M 6.1%
- Europe 1.24M 0.5%
- Other Countries 582.00K 0.3%
Fiscal year ended Dec 31, 2025 See the full STO:BINV breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 226.50M | 181.81M | 406.86% |
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% |
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | 93.74M | 55.19M | 143.18% |
| Dec 31, 2018 | 38.55M | -6.47M | -14.36% |
| Dec 31, 2017 | 45.01M | -26.27M | -36.85% |
| Dec 31, 2016 | 71.28M | 55.36M | 347.62% |
| Dec 31, 2015 | 15.93M | -31.01M | -66.07% |
| Dec 31, 2014 | 46.93M | -34.78M | -42.56% |
| Dec 31, 2013 | 81.71M | 38.77M | 90.27% |
| Dec 31, 2012 | 42.95M | -81.70M | -65.55% |
| Dec 31, 2011 | 124.65M | 41.78M | 50.42% |
| Dec 31, 2010 | 82.87M | 2.21M | 2.74% |
| Dec 31, 2009 | 80.66M | -171.48M | -68.01% |
| Dec 31, 2008 | 252.14M | 108.70M | 75.78% |
| Dec 31, 2007 | 143.44M | 92.61M | 182.20% |
| Dec 31, 2006 | 50.83M | 22.63M | 80.26% |
| Dec 31, 2005 | 28.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 127.95M |
| IRLAB Therapeutics AB | 71.79M |
| Abera Bioscience AB | 9.10M |
| Elicera Therapeutics AB | 7.79M |
| Xintela AB | 3.03M |
| Simris Group AB (PUBL) | 1.14M |
| Diamyd Medical AB | 477.00K |
| Alzinova AB | 180.00K |
BioInvent International AB News
- 10 days ago - BioInvent International AB Transcript: Aktiespararna Digital temakväll - Life Science - Transcripts
- 18 days ago - BioInvent International AB Transcript: BioStock Life Science Summit 2026 - Transcripts
- 19 days ago - BioInvent downgraded to Hold from Buy at Pareto - TheFly
- 24 days ago - BioInvent International AB Earnings Call Transcript: Q3 2026 - Transcripts
- 24 days ago - BioInvent International AB Quarterly report: Q3 2026 - Filings
- 24 days ago - BioInvent International AB Slides: Q3 2026 - Filings
- 4 weeks ago - BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer - Accesswire
- 4 weeks ago - BioInvent International AB Slides: Corporate presentation - Filings